AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32050899
Drug: G-MEDSS intervention
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G-MEDSS intervention (Computerised Clinical Decision Support System)
Trial: 32050899
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care HMR service (without G-MEDSS)
Trial: 35588245
Drug: Viloxazine extended-release
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine extended-release (600 mg/d)
Trial: 32768465
Drug: Enalapril (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (initial dose 0.10 mg/kg/d, median maximal dose 0.38 mg/kg/d)
Trial: 35019882
Drug: Yoga exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga exercise program (one hour twice weekly for 12 weeks)
Trial: 35881199
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (SH) eyedrops, applied 4 times daily for 2 months
Trial: 35881199
Drug: Semi‐fluorinated alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi‐fluorinated alkane (SFA) eyedrops, applied 4 times daily for 2 months
Trial: 36564573
Drug: Subcision combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcision combined with cross-linked HA filler injection
Trial: 33539400
Drug: Self-Administered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Administered therapy (SAT)
Trial: 33668674
Drug: Cheddar cheese
RxNorm normalized name: Cheddar cheese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cheddar cheese (20 g protein)
Trial: 35369650
Drug: TMX-049 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMX-049 200 mg
Trial: 35369650
Drug: TMX-049 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMX-049 40 mg
Trial: 35369650
Drug: TMX-049 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMX-049 200 mg and 40 mg
Trial: 34807241
Drug: Ciclesonide MDI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide MDI, 160 μg per actuation, 2 actuations twice a day (total daily dose, 640 μg) for 30 days
Trial: 32897519
Drug: Bacillus clausii
RxNorm normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus clausii (Enterogermina®) capsules, 2 × 10^9 spores, three times daily for 2 weeks
Trial: 32897519
Drug: Placebo, three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, three times daily for 2 weeks
Trial: 616410548
Drug: ipragliflozin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipragliflozin (50 mg/day)
Trial: 35389028
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid group (TA 250 mg twice daily)
Trial: 32646428
Drug: Trehalose (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose (3.3 g/day)
Trial: 32646428
Drug: Sucrose (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (3.3 g/day)
Trial: 35320642
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day)
Trial: 35320642
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control)
Trial: 35320642
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high dose of liposomal amphotericin B
Trial: 34160597
Drug: Absorbable antibiotic
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable antibiotic eluting envelope
Trial: 32307155
Drug: Oral electrolyte
RxNorm normalized name: Hydralyte Oral Electrolyte Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral electrolyte solution (OES) administered in milk replacer (MR) and water (3 L at 1300 and 2200 h) for 4 d
Trial: 32307155
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CON) receiving a small dose of whey (n = 12)
Trial: 33550525
Drug: Device-aided therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device-aided therapies (CSAI, LCIG, DBS)
Trial: 32157765
Drug: Cream A
RxNorm normalized name: KIT, CREAM AND GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream A (without tranexamic acid)
Trial: 32157765
Drug: Cream B
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream B (with tranexamic acid)
Trial: 32157765
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (Group C)
Trial: 32938411
Drug: Drug Sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Sensitive TB (DS-TB) treatment
Trial: 32938411
Drug: Multi Drug
RxNorm normalized name: At Home Multi Drug Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi Drug Resistant Tuberculosis (MDR TB) treatment
Trial: 32938411
Drug: General TB
RxNorm normalized name: TB-402
DrugBank: TB-402 (DB06050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General TB treatment
Trial: 32053141
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous adipose tissue-derived stromal vascular fraction (ADSVF) into 1 or 2 vocal folds.
Trial: 32899067
Drug: Direct-acting oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting oral anticoagulants
Trial: 33903287
Drug: Traditional anticoagulants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional anticoagulants
Trial: 33675348
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg resveratrol
Trial: 33675348
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g resveratrol
Trial: 32934137
Drug: Pegloticase in
RxNorm normalized name: pegloticase Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase in combination with Methotrexate (MTX)
Trial: 32565122
Drug: 1% THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% THC dose of cannabis
Trial: 32565122
Drug: 4% THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% THC dose of cannabis
Trial: 32565122
Drug: 7% THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% THC dose of cannabis
Trial: 32565122
Drug: THC plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC plasma levels between 16 ng/mL and 31 ng/mL
Trial: 36092192
Drug: Intralesional MMR
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional MMR (0.3 ml)
Trial: 36092192
Drug: Subcutaneous MMR
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous MMR (0.5 ml)
Trial: 33039134
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine
Trial: 33909172
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose glucocorticoids (GC) for induction and maintenance of remission
Trial: 33909172
Drug: Mepolizumab (interleukin-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (interleukin-5 inhibitor)
Trial: 33909172
Drug: Alternative immunosuppressive
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative immunosuppressive agents (e.g. mycophenolate mofetil, abatacept)
Trial: 33909172
Drug: Prolonged course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged course of maintenance treatment
Trial: 32192596
Drug: Gonadotropin, clomiphene,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin, clomiphene, or letrozole with IUI for four or fewer treatment cycles
Trial: 33858493
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus investigational treatment (IT) with cisternal lavage using urokinase, nimodipine, and Ringer’s solution
Trial: 32302056
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of macitentan (film‐coated adult formulation)
Trial: 32302056
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of macitentan (two 5 mg dispersible tablets pediatric formulation)
Trial: 33982418
Drug: Finely milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finely milled 30 mg ER tablets (EDR 6.9)
Trial: 33982418
Drug: Coarsely milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coarsely milled 30 mg ER tablets
Trial: 33982418
Drug: Finely milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finely milled 80 mg ER tablets (EDR 4.9)
Trial: 33982418
Drug: Finely milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finely milled IR tablets
Trial: 33755051
Drug: Faecal immunochemical
RxNorm normalized name: Enterococcus faecalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faecal immunochemical test (FIT) at cut-off values of 2 μg/g
Trial: 33755051
Drug: Faecal immunochemical
RxNorm normalized name: Enterococcus faecalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faecal immunochemical test (FIT) at cut-off values of 10 μg/g
Trial: 33755051
Drug: Faecal immunochemical
RxNorm normalized name: Enterococcus faecalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faecal immunochemical test (FIT) at cut-off values of 150 μg/g
Trial: 32207414
Drug: Cervical manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical manual therapy alone (Control)
Trial: 32207414
Drug: Cervical along
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical along with thoracic manual therapy (Experimental)
Trial: 36341464
Drug: Protein/peptide vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein/peptide vaccines
Trial: 32214298
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine 10 mg/kg
Trial: 38869647
Drug: Oxaliplatin-based chemotherapy
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin-based chemotherapy
Trial: 35179551
Drug: Ivermectin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (0.4 mg/kg body weight daily for 5 days) + standard of care
Trial: 32117545
Drug: Standard Ponseti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Ponseti casting technique (once-weekly)
Trial: 32117545
Drug: Accelerated Ponseti
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Ponseti casting technique (twice-weekly)
Trial: 32063564
Drug: L‐Carnosine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐Carnosine 400 mg twice daily
Trial: 32063564
Drug: L‐Carnosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐Carnosine
Trial: 33566465
Drug: Enoxaparin prophylaxis
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin prophylaxis started less than 24 hours after insertion of central venous catheter, adjusted to anti-Xa level of 0.2-0.5 international units/mL
Trial: 36108676
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B complex supplementation (thiamine 10 mg, riboflavin 4 mg, nicotinamide 40 mg, dexpanthenol 6 mg)
Trial: 36125471
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg, n=51)
Trial: 32178964
Drug: Atezolizumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (840 mg) plus nab-paclitaxel (100 mg/m2)
Trial: 32178964
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus nab-paclitaxel (100 mg/m2)
Trial: 32822325
Drug: Conventional yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yoghurt (300 grams daily for 8 weeks)
Trial: 32822325
Drug: Organic yoghurt
RxNorm normalized name: Organix Complete
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic yoghurt (300 grams daily for 8 weeks)
Trial: 34102253
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1; ribociclib 600 mg/day, 3 weeks on, 1 week off)
Trial: 34102253
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1)
Trial: 32182916
Drug: PSA_MSA algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA_MSA algorithm (combination of pixel-swapping algorithm and modified simulated annealing algorithm)
Trial: 36401728
Drug: Melatonin plus
RxNorm normalized name: Nature's Truth Melatonin Plus L-Theanine 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin plus standard treatment
Trial: 36078602
Drug: Acupressure wristband
RxNorm normalized name: ACUPRESSURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure wristband at P6 point applied three times daily
Trial: 36078602
Drug: Regular doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular doses of intravenous antiemetics
Trial: 36795891
Drug: Control medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control medication
Trial: 34396485
Drug: Mini implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini implants in conjunction with class II elastics
Trial: 34396485
Drug: Class II
RxNorm normalized name: HLA class II antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class II elastics therapy (control group)
Trial: 34266402
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment (Photon IMRT 50 Gy in 25 fractions + boost using 8 × 3 Gy carbon ions)
Trial: 34246347
Drug: Ipatasertib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib (400 mg once daily) plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Trial: 34246347
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Trial: 34047723
Drug: Ketorolac group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac group (received standard-of-care protocol, intravenous ketorolac at completion of procedure, and oral ketorolac on discharge)
Trial: 34047723
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received standard-of-care pain protocol, including oxycodone-acetaminophen 5 to 325 mg on discharge)
Trial: 39210472
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg daily for 3 months
Trial: 32660564
Drug: sc-LCPUFA (1.19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc-LCPUFA (1.19 g/day)
Trial: 36203486
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg Rimazolam
Trial: 36203486
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg Rimazolam
Trial: 33545574
Drug: Compound Da-Cheng-Qi
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Da-Cheng-Qi Decoction (CDCQD), 100 ml twice a day for 7 days
Trial: 33545574
Drug: Compound Da-Cheng-Qi
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Da-Cheng-Qi Decoction (CDCQD)
Trial: 34000227
Drug: Islatravir 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 0.25 mg + doravirine (100 mg) + lamivudine (300 mg)
Trial: 34000227
Drug: Islatravir 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 0.75 mg + doravirine (100 mg) + lamivudine (300 mg)
Trial: 34000227
Drug: Islatravir 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 2.25 mg + doravirine (100 mg) + lamivudine (300 mg)
Trial: 34000227
Drug: Doravirine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (100 mg) + lamivudine (300 mg) + TDF (300 mg)
Trial: 34000227
Drug: Islatravir 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 2.25 mg group
Trial: 36375643
Drug: Liraglutide therapy
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide therapy
Trial: 33929379
Drug: Induction infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction infliximab therapy
Trial: 35836627
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of injection terlipressin 0.02 µg/kg/min infusion and injection norepinephrine 0.01 µg/kg/min infusion
Trial: 35836627
Drug: Norepinephrine 0.01
RxNorm normalized name: norepinephrine 0.016 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.01 µg/kg/min infusion alone
Trial: 35836627
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of injection terlipressin and norepinephrine
Trial: 36706355
Drug: Ipilimumab monotherapy
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab monotherapy
Trial: 35996199
Drug: TQG202 prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQG202 prophylaxis (30 ± 5 IU/kg initial dose for 24 weeks)
Trial: 33920292
Drug: Caffeine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2 × 2.5 mg/kg/24 h)
Trial: 32652314
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (IAIs) 2 mg every 4 weeks
Trial: 32652314
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (IAIs) 2 mg every 8 weeks after 3 initial monthly doses
Trial: 33077012
Drug: Lurasidone (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (20-80 mg/day)
Trial: 32320100
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (preoperative education, postoperative abdominal massage, and polyethylene glycol 4,000)
Trial: 32320100
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment and Preoperative education only
Trial: 33583000
Drug: Nutrition intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition intervention (individual nutrition counseling) aiming for daily protein intake of 1.0-1.2 g/kg body weight, energy intake of 25-30 kcal/kg body weight/day, and serum vitamin D concentration ≥ 75 mmol/L
Trial: 32067684
Drug: Experimental induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental induction chemotherapy with two additional courses of topotecan, cyclophosphamide, and etoposide followed by standard induction chemotherapy (eight courses in total)
Trial: 32067684
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy with six chemotherapy courses
Trial: 32067684
Drug: Experimental induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental induction chemotherapy with two additional courses of topotecan, cyclophosphamide, and etoposide followed by standard induction chemotherapy
Trial: 34656952
Drug: Skin roasted
RxNorm normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin roasted peanuts (SRP, 25 g/day)
Trial: 34656952
Drug: Peanut butter
RxNorm normalized name: Zbar Peanut Butter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut butter (PB, 32 g/day)
Trial: 34656952
Drug: Control butter
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control butter (CB, 32 g/day)
Trial: 34077818
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction of docetaxel
Trial: 36735400
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg daily for 12 months)
Trial: 36735400
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 12 months)
Trial: 32527268
Drug: Real dual‐tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real dual‐tDCS (2 mA for 20 mins) with concurrent paretic hand exercise